Glaukos (GKOS) Scheduled to Post Earnings on Monday

Glaukos (NYSE:GKOS) will release its earnings data after the market closes on Monday, November 4th. Analysts expect Glaukos to post earnings of ($0.52) per share for the quarter. Glaukos has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The company had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. During the same period in the prior year, the business posted ($0.55) earnings per share. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Price Performance

NYSE:GKOS opened at $130.59 on Monday. Glaukos has a 52 week low of $59.22 and a 52 week high of $136.60. The stock’s fifty day moving average is $129.07 and its two-hundred day moving average is $118.41. The company has a market capitalization of $6.58 billion, a P/E ratio of -45.34 and a beta of 1.02. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19.

Insider Activity at Glaukos

In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director now owns 30,119 shares in the company, valued at $3,614,280. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now directly owns 30,119 shares of the company’s stock, valued at $3,614,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $13,216,581.84. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,250 shares of company stock valued at $4,825,873 over the last 90 days. 6.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GKOS has been the topic of a number of recent analyst reports. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Wells Fargo & Company upped their price objective on shares of Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Truist Financial lifted their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Morgan Stanley lifted their price objective on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Finally, Piper Sandler set a $140.00 target price on Glaukos in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $130.45.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.